Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century
RUHS Journal of Health Science · 2025
DOI: 10.37821/ruhsjhs.10.2.2025.869 ↗Kurz gefasst
Fachartikel in der Zeitschrift RUHS Journal of Health Science, 2025. Verfasst von Rajeev Gupta.
Abstract (Originalsprache)
Polypill, as a fixed dose combination of cardioprotective therapies, has been developed for primary prevention of cardiovascular diseases (CVD) with the premise that raised blood pressure, LDL cholesterol, and platelet adhesiveness are the prime culprits. It was hypothesised that this combination could prevent 80% of heart attacks, but evidence from randomised clinical trials has culled this expectation to 30-45%. The use of aspirin in the polypill is debatable, large meta-analysis have reported that the risk-benefit ratio exceeds unity. Recent epidemiological studies have reported that cardiometabolic conditions obesity, metabolic syndrome, and diabetes, as well as cardiovascular-kidney-metabolic syndrome, are also important CVD risk factors. None of the presently available polypills address the latter. Novel metabolic drugs such as incretin-mimetics fulfil many of the criteria of a polypill for CVD and could be combined with available blood pressure and lipid-lowering drugs to develop a polypill for the 21st century.
Zitieren
APA
Gupta, R. (2025). Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century. RUHS Journal of Health Science. https://doi.org/10.37821/ruhsjhs.10.2.2025.869
Vancouver
Gupta R. Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century. RUHS Journal of Health Science. 2025. doi:10.37821/ruhsjhs.10.2.2025.869
BibTeX
@article{Gupta2025,
author = {Gupta, Rajeev},
title = {Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century},
journal = {RUHS Journal of Health Science},
year = {2025},
doi = {10.37821/ruhsjhs.10.2.2025.869}
}
EUVIMED